Addressing the need for an infection prevention and control framework that incorporates the role of surveillance: a discussion paper

2013 ◽  
Vol 70 (3) ◽  
pp. 533-542 ◽  
Author(s):  
Brett G. Mitchell ◽  
Anne Gardner
2017 ◽  
Vol 22 (2) ◽  
pp. 83-88 ◽  
Author(s):  
Brett G. Mitchell ◽  
Deborough MacBeth ◽  
Kate Halton ◽  
Anne Gardner ◽  
Lisa Hall

2019 ◽  
Vol 20 (3) ◽  
pp. 116-121
Author(s):  
Martyn AC Wilkinson ◽  
Evonne T Curran ◽  
Christina R Bradley

Choosing which disinfectant(s) to use in any particular healthcare environment is a far from trivial task and one that is undertaken by Infection Prevention and Control (IPC) professionals on a regular basis. The recent proliferation in the number and type of products designed to disinfect healthcare surfaces makes for a seemingly bewildering range of options. The primary factor to consider is whether the disinfectant is capable of killing the likely (but unknown) microbial challenge. For reusable non-invasive care equipment, standardised testing provides objective evidence for IPC teams. This second paper seeks to explain these tests and the conditions under which they are performed to aid in the IPC teams’ disinfection selection.


2001 ◽  
Vol 22 (7) ◽  
pp. 459-463 ◽  
Author(s):  
Andrew E. Simor

AbstractHospital infection prevention and control programs rely extensively on diagnostic microbiology laboratory testing. However, specimens for microbiological evaluation are less likely to be obtained from elderly residents of long-term–care facilities (LTCFs). In this article, issues regarding laboratory utilization and the potential role of the microbiology laboratory in infection prevention and control programs in LTCFs are reviewed. The role of the laboratory in infection surveillance, in the management of antimicrobial resistance, and in outbreak investigation are highlighted.


Author(s):  
Jarapla Srinivas Nayak ◽  
Tittu Thomas James ◽  
Shubham Menaria ◽  
Dr. Centina Rose John ◽  
Dr. Dhargave Pradnya

COVID-19 is a new pandemic disease which was reported initially at the city of Wuhan in the Hubei province ofChina on 31 December 2019. 1Recent events have reported its presence in more than 150 countries and with 132758 confirmed cases and a total of 4955 deaths as on 13th March 2020.2Although the death rate due to the disease is 6% or less, the persons who are affected in a short span of time is at an alarming rate.3 In this context, World Health Organization (WHO) have declared the disease as pandemic on 11th March 2020.


2020 ◽  
Vol 53 (1) ◽  
pp. 43-55
Author(s):  
William Marty Martin ◽  
Yvette Lopez ◽  
Thomas P. Flannery ◽  
Bill Dixon

Infectious diseases at work can be endemic such as seasonal influenza and emerging such as the novel coronavirus 2019. Infectious diseases have an impact on employees and other types of workers. Compensation and benefits professionals are often at the forefront of preventing workplace infections, addressing workplace infections, and ensuring the continuity of talent when workplace outbreaks and business shutdowns occur. This article provides an overview of pertinent laws, key compensation decisions, and ways to refocus existing benefit programs to meet the challenge of not only just safety, health, and wellness but also infection prevention and control.


Sign in / Sign up

Export Citation Format

Share Document